127 related articles for article (PubMed ID: 37682730)
1. Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
Lu S; Guo X; Li Y; Liu H; Zhang Y; Zhu H
Cancer; 2024 Jan; 130(1):18-30. PubMed ID: 37682730
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Porte M; Vaudron A; Crequit P; Vaugier L; Chatellier T; Fronteau C; Raimbourg J; Goronflot T; Bennouna J; Pons-Tostivint E
Clin Lung Cancer; 2024 Mar; 25(2):e101-e111.e2. PubMed ID: 38072729
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
Ma J; Tian Y; Hao S; Zheng L; Hu W; Zhai X; Meng D; Zhu H
J Neurooncol; 2022 Sep; 159(3):685-693. PubMed ID: 35976547
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
Han J; Fu C; Li B
Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract][Full Text] [Related]
6. Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer.
Sun H; Xu L; Wang Y; Zhao J; Xu K; Qi J; Yuan Z; Zhao L; Wang P
Radiat Oncol; 2018 Dec; 13(1):250. PubMed ID: 30563554
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
Yao Y; Li B; Song R; Yang L; Zou B; Wang L
Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
10. Generation of a New Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer Treated With Whole Brain Radiotherapy (BMS-Score) and Validation of Two Other Indices.
Bernhardt D; König L; Aufderstrasse S; Krisam J; Hoerner-Rieber J; Adeberg S; Bozorgmehr F; El Shafie R; Lang K; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Marcrom S; Debus J; Steins M; Rieken S
Clin Lung Cancer; 2018 Jul; 19(4):340-345. PubMed ID: 29373273
[TBL] [Abstract][Full Text] [Related]
11. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
13. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
14. Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy.
Stanic K; Vrankar M; But-Hadzic J
Radiol Oncol; 2020 Jul; 54(3):353-363. PubMed ID: 32726294
[TBL] [Abstract][Full Text] [Related]
15. Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.
Charpidou A; Tsagouli S; Gkiozos I; Grapsa D; Moutsos M; Kiagia M; Syrigos K
Clin Exp Metastasis; 2016 Jun; 33(5):453-60. PubMed ID: 27209468
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of thoracic radiotherapy in extensive stage small cell lung cancer with baseline brain metastases: a multi-institutional retrospective cohort study.
Zheng Z; Yuan X; Zhou Y; Chu L; Yang X; Ni J; Chu Q; Chu X; Liu Y; Zhu Z
Ann Transl Med; 2023 Jan; 11(2):60. PubMed ID: 36819545
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
18. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of immune checkpoint inhibitors plus anlotinib in small cell lung cancer with brain metastases: a retrospective, multicentre study.
Zhou S; Ren F; Li C; Jiang L; Meng X; Huang Z
J Neurooncol; 2022 Dec; 160(3):631-642. PubMed ID: 36346496
[TBL] [Abstract][Full Text] [Related]
20. Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer.
Hou R; Li H; Cao J; Song X; Zhang X; Wang W
Ann Palliat Med; 2021 Jan; 10(1):29-36. PubMed ID: 33440957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]